Ambicin

Drug Profile

Ambicin

Alternative Names: Ambicin N; Nisin; Nisin A

Latest Information Update: 11 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nutrition 21
  • Class Antibacterials; Antiseptics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute enterocolitis; Gingivitis; Gram-negative infections; Gram-positive infections; Impetigo; Intestinal infections; Nosocomial infections; Peptic ulcer

Most Recent Events

  • 20 Dec 2006 Discontinued - Preclinical for Intestinal infections in Japan (PO)
  • 20 Dec 2006 Discontinued - Preclinical for Intestinal infections in USA (PO)
  • 16 Aug 2000 AMBI licenses nisin rights to Biosynexus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top